Detalhe da pesquisa
1.
Patient-derived tumor xenograft study with CDK4/6 inhibitor plus AKT inhibitor for the management of metastatic castration-resistant prostate cancer.
Mol Cancer Ther
; 2024 Mar 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38442920